Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who’s Hired? BIO’s Duncan Joins AAM

As Coherus Names New Chair Of Scientific Advisory Board

Executive Summary

The Association for Accessible Medicines has appointed former Biotechnology Innovation Organization representative Joanne Duncan as its new chief operating officer.  Meanwhile, Coherus has names the new chair of its scientific advisory board, while women’s health specialist Theramex has added to its board of directors

You may also be interested in...



JB Chemicals Acquires Several Sanzyme Brands

JB Chemicals has purchased a number of leading brands from Sanzyme, which it plans to scale up and institutionalize within India. The transaction, worth over $80m, is expected to close within the next two weeks.

AAM Unveils ‘Long Overdue’ Membership Roles

The US Association for Accessible Medicines has for the first time appointed two member-focused roles within its organization, as long-serving policy executive Christine Simmon was also handed a promotion.

Kelix Strikes A Deal To Acquire 14 Oncology Injectables

Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel